Chemotherapy may be delivered based on an integrated view of tumour dynamics

IET Systems Biology

Volumn 3, Issue 3, 2009, Pages 180-190

  Ribba, Benjamin ^a,b,e   You, B ^a,b,c   Tod, M ^a,b   Girard, P ^a,b   Tranchand, B ^a,b,d   Trillet Lenoir, V ^a,b,c   Freyer, G ^a,b,c  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITÉ CLAUDE BERNARD LYON 1   (France)

^c CENTRE HOSPITALIER LYON SUD   (France)

^d CENTRE LÉON BÉRARD   (France)

^e UNIVERSITÉ DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTHERAPY; CONTROLLED DRUG DELIVERY; CYTOLOGY; DISEASES; FLUID MECHANICS; TARGETED DRUG DELIVERY; TUMORS;

CELL CYCLE PHASE; CELL CYCLE REGULATION; CHEMOTHERAPY TREATMENT; DISEASE MODELING; PRIMARY EFFECTS; TISSUE LEVELS; TREATMENT EFFECTS; TUMOUR GROWTH;

CELLS;

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT;

ARTICLE; BIOMECHANICS; CELL CYCLE REGULATION; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG RESEARCH; DRUG TARGETING; MALIGNANT NEOPLASTIC DISEASE; MATHEMATICAL MODEL; OSCILLATION; PATHOPHYSIOLOGY; PHARMACOLOGICAL PARAMETERS; TARGET CELL; TUMOR; TUMOR CELL; TUMOR GROWTH;

EID: 66249093165     PISSN: 17518849     EISSN: None     Source Type: Journal    
DOI: 10.1049/iet-syb.2008.0104     Document Type: Article

References (19)

1. Gurney, H.: 'Dose calculation of Anticancer drugs: a review of the current practice and introduction of an alternative', J. Clin. Oncol., 1996, 14, (9), p. 2590-2611
2. Parsad, S.D., and Ratain, M.J.: 'Prescribing oral chemotherapy', BMJ, 2007, 334, (7590), p. 376
3. Kummar, S., Kinders, R., and Rubinstein, L.: Et al. 'Compressing drug development timelines in oncology using phase '0' trials', Nat. Rev. Cancer, 2007, 7, (2), p. 131-139
4. Shaked, Y., Bocci, G., and Munoz, R.: Et al. 'Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose', Curr. Cancer Drug Targets, 2005, 5, (7), p. 551-559
5. Blackhall, F., Ranson, M., and Thatcher, N.: Where next for gefitinib in patients with lung cancer?', Lancet Oncol., 2006, 7, (6), p. 499-507
6. Post, T.M., Freijer, J.I., Dejongh, J., and Danhof, M.: 'Disease system analysis: Basic disease progression models in degenerative disease', Pharm. Res., 2005, 22, (7), p. 1038-1049
7. Ribba, B., Saut, O., Colin, T., Bresch, D., Grenier, E., and Boissel, J.P.: 'A multiscale mathematical model of avascular tumor growth to investigate the therapeutic benefit of anti-invasive agents', J. Theor. Biol., 2006, 243, (4), p. 532-541
8. Sobrero, A.F., Aschele, C., and Bertino, J.R.: 'Fluorouracil in colorectal cancer - A tale of two drugs: Implications for biochemical modulation', J. Clin. Oncol., 1997, 15, (1), p. 368-381
9. Agur, Z.: 'Randomness, synchrony and population persistence', J. Theor. Biol., 1985, 112, p. 677-693
10. Cojocaru, L., and Agur, Z.: 'A theoretical analysis of interval drug dosing for cell-cycle-phase-specific drugs', Math. Biosci., 1992, 109, (1), p. 85-97 0025-5564
11. Ribba, B., Colin, T., and Schnell, S.: 'A multiscale mathematical model of cancer, and its use in analyzing irradiation therapies', Theor. Biol. Med. Model, 2006, 3, p. 7
12. Ambrosi, D., and Preziosi, L.: 'On the closure of mass balance models for tumor growth', Math. Models Methods Appl. Sci., 2002, 12, p. 737-754 10.1142/S0218202502001878 0218-2025
13. Blagosklonny, M.V., and Pardee, A.B.: 'The restriction point of the cell cycle', Cell Cycle, 2002, 1, (2), p. 103-110
14. Kufe, D.W., Pollock, R.E., Weichselbaum, R.R., Bast, R.C., Gansler, T.S., and Holland, J.F.: 'Cancer medicine', 6th (B.D. Inc., Hamilton, Canada 2003)
15. Altinok, A., Levi, F., and Goldbeter, A.: 'A cell cycle automation model for probing circadian patterns of anticancer drug delivery', Adv. Drug Deliv. Rev., 2007, 59, (9-10), p. 1036-1053
16. Daruwalla, J., and Christophi, C.: 'The effect of hyperbaric oxygen therapy on tumour growth in a mouse model of colorectal cancer liver metastases', Eur. J. Cancer, 2006, 42, (18), p. 3304-3311
17. Ribba, B., Marron, K., Agur, Z., Alarcon, T., and Maini, P.K.: 'A mathematical model of Doxorubicin treatment efficacy for non-Hodgkin's lymphoma: Investigation of the current protocol through theoretical modelling results', Bull. Math. Biol., 2005, 67, (1), p. 79-99 0092-8240
18. Hahn, W.C., and Weinberg, R.A.: 'Modelling the molecular circuitry of cancer', Nat. Rev. Cancer, 2002, 2, (5), p. 331-341
19. Hanahan, D., and Weinberg, R.A.: 'The hallmarks of cancer', Cell, 2000, 100, (1), p. 57-70